Brain-targeted cyclosporine A nano-drug as well as preparation method and application thereof
By fusing platelet membrane and mitochondrial membrane in cyclosporine A nanodrug and modifying the functional molecule DSPE-PEG2000-RVG29, the precise delivery and neuroprotection of cyclosporine A to traumatic brain injury sites is achieved, and the existing solution is solved The problem of cyclosporine A is difficult to cross the blood-brain barrier and immunosuppression in the technology, which significantly improves neurological damage and inflammatory response.
Patent Information
- Application Number
- CN202411200563.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-03
AI Technical Summary
Due to the impaired immune function of patients with traumatic brain injury, existing cyclosporine A is difficult to effectively cross the blood-brain barrier, resulting in significant immunosuppression in the treatment of traumatic brain injury and lack of selective targeting of neuronal mitochondria. Limits its therapeutic potential.
The brain-targeted cyclosporine A nanodrug RMP-LipCsA is used to modify the functional molecule DSPE-PEG2000-RVG29 by fusing the platelet membrane and mitochondrial membrane, and bind to brain microvascular endothelial cells to mediate penetration of blood and brain through RVG29. The barrier and targets the endogenous mitochondria of cells through the mitochondria membrane, reducing binding to intracellular CypA and reducing immunosuppression.
The precise delivery and neuroprotection of cyclosporine A on the sites of traumatic brain injury is achieved, which reduces the side effects of immunosuppression, significantly improves neurological damage and inflammatory response, and provides a new important means to treat traumatic brain injury.
Smart Images

Figure CN119055793A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biological targeted delivery systems, and in particular to a brain-targeted cyclosporine A nano drug and a preparation method and application thereof. Background Art
[0002] Traumatic brain injury (TBI) has a high disability and mortality rate, causing approximately 50 million new cases of disability and 1.6 million deaths each year. TBI may be caused by a variety of reasons, such as falls, traffic accidents, violence, sports or explosion injuries, and cause primary and secondary damage to the brain. TBI causes pathological changes in local brain tissue, cellular level, and molecular level, produces proinflammatory factors and toxic substances, further damages the blood-brain barrier, increases intracranial pressure, aggravates local brain ischemia, and aggravates neuronal cell death.
[0003] Cyclosporine A (CsA) is an important drug for the treatment of traumatic brain injury by reducing neuronal mitochondrial dysfunction to avoid neuronal apoptosis. However, CsA also has the limitations of low solubility, poor blood-brain barrier (BBB) permeability, and immunosuppressive effects. Patients with traumatic brain injury are highly susceptible to infection due to impaired immune function, and the immunosuppressive effect of CsA is even more worrying in the treatment of TBI.
[0004] Therefore, in order to realize the therapeutic potential of CsA for TBI, it is necessary to achieve effective delivery of CsA to the site of TBI brain injury and selective targeting of CsA to neuronal mitochondria while avoiding systemic immunosuppression. Summary of the invention
[0005] The present invention aims to provide a brain-targeted cyclosporine A nanomedicine (RMP-Lip CsA ). To expand on this, it means:
[0006] Brain-targeted cyclosporine A nanomedicines, including:
[0007] (a) Fusion membrane, which is a composite membrane, comprising a mitochondrial membrane and a cell membrane or organelle membrane fused with the mitochondrial membrane; (b) intercalated molecules, which are modified on the fusion membrane; intercalated molecules are functional molecules that cross the blood-brain barrier;
[0008] (c) The inner lumen is cyclosporine A liposomes; the inner lumen is surrounded by a fusogenic membrane.
[0009] The nanomedicine obtained from the above: brain-targeted cyclosporine A nanomedicine (RMP-Lip CsA ) in the membrane coating can drive the RMP-Lip CsABinding to brain microvascular endothelial cells, and then mediating blood-brain barrier penetration through functional factors, the mitochondrial membrane in the membrane coating can drive RMP-Lip CsA Targeting the endogenous mitochondria of cells, further recruiting drugs to the site of injury and precisely delivering drugs to the mitochondria in damaged brain cells, in order to alleviate traumatic brain injury (TBI) and save its neurological function.
[0010] Specifically, the applicant has found through research that cyclosporine A (CsA) is a polypeptide composed of 11 amino acids and is a commonly used immunosuppressant in clinical practice. At the same time, it is also an effective neuroprotective drug. Studies have shown that CsA has a potential therapeutic effect on transient cerebral ischemia. It can play a therapeutic role in various diseases through various mechanisms such as anti-oxidative stress, anti-inflammation, and anti-apoptosis, and stabilize mitochondrial function, especially in I / R injury (ischemia-reperfusion injury).
[0011] Current treatments for TBI include surgical removal of the injury, and rehabilitation therapy is required after TBI, including memory, language ability, motor skills, etc. to restore the patient's condition and improve the quality of life. However, due to the lack of treatments to prevent secondary injuries, many TBI patients are left with varying degrees of neurological dysfunction.
[0012] At the same time, with the rapid development of biomaterials, nanomedicine and pharmacology, the drug delivery across the blood-brain barrier to targeted injury sites has gradually shown a glimmer of hope. The discovery and modification of various transmembrane peptides and blood-brain barrier receptor (BBR)-specific ligands have greatly improved the ability of drug-loaded drugs to penetrate the blood-brain barrier. Studies have found that the 29-amino acid peptide RVG29 derived from the rabies virus glycoprotein can bind to at least the nicotinic acetylcholine receptor (NAchR) and the GABAB receptor, and transport its modified target substances across the blood-brain barrier to the brain parenchyma through receptor-mediated transcellular interactions or pit-mediated energy-dependent endocytosis.
[0013] In addition, cell membrane-coated nanoparticles have attracted attention due to their biomimetic properties, which provide a strategy for targeting nanoparticles that cross the blood-brain barrier to reach focal areas of the brain. In brain I / R injury after TBI, platelet membranes can further migrate to the site of brain injury at the initial stage of inflammation through adhesion proteins on the membrane, such as CD61 and ICAM-1 expressed on endothelial cells. Since the process of platelet membranes homing to the brain and adhering to brain vascular endothelial cells is very similar to the first stage of nanoparticle transport through the blood-brain barrier (BBB), that is, nanoparticles are targeted to the brain from the blood and bind to receptors on the apical membrane of the BBB, and then platelet membranes are selectively recruited to specific injury sites under the guidance of chemokine concentration gradients. This means that after crossing the BBB, nanomedicines can reach where they are most needed.
[0014] Therefore, we prepared platelet-coated cyclosporine A liposomes (P-Lip CsA ), which can bind to the BBB and target damaged cells after crossing the blood-brain barrier.
[0015] However, P-Lip CsA There are still two issues to be resolved. One is P-Lip CsA It still lacks BBB-penetration ability and cannot connect the inside and outside of the BBB to achieve the perfect effect of neutrophil membrane-encapsulated nanoparticles targeting brain injury. Second, CsA has limitations such as poor water solubility, high plasma protein binding, and low blood-brain barrier (BBB) permeability, especially the immunosuppressive side effects caused by its multiple biological activities. These limitations hinder the therapeutic potential of CsA in TBI.
[0016] In this technology, we use: the platelet membrane has a damage targeting effect, and the mitochondrial membrane has a mitochondrial targeting effect, so the fusion of the two membranes can achieve cascade targeting to the mitochondria in damaged cells. And CsA, as an immunosuppressant, combines with CypA to inhibit the immune activation of T cells and is used for immunosuppressive therapy. When it combines with CypD under pathological conditions, it protects cells from damage by inhibiting the opening of the mitochondrial transition pore. When it combines with CypA in the cytoplasm to play a neuroprotective role in TBI, it puts TBI patients at greater risk of infection. Therefore, the fusion protein on the surface of the mitochondrial membrane is used to deliver nanomedicines to the mitochondria in a targeted manner, so that it binds to CypD in the mitochondria, reduces the binding with CypA in the cytoplasm, and thus reduces the immunosuppressive effect.
[0017] In view of this, according to one aspect of the present invention, a brain-targeted cyclosporine A nanomedicine (RMP-Lip CsA ), the fusion membrane of the platelet membrane and the mitochondrial membrane is modified with a functional molecule that crosses the blood-brain barrier, and the functional molecule that crosses the blood-brain barrier is DSPE-PEG 2000 -RVG29. RMP-Lip CsA Platelet membrane coating can drive RMP-Lip CsA It binds to brain microvascular endothelial cells by homing, then penetrates the blood-brain barrier through RVG29, and then further recruits CsA to the injured site and accurately delivers it to the injured brain cells. Then, through the mitochondrial targeting function of the mitochondrial membrane, it accurately targets it to the endogenous mitochondria of the cell, binds to cyclophilin A in the mitochondria, improves mitochondrial function, and exerts a neuroprotective effect; and reduces intracellular targeting, reduces the binding of CsA to intracellular cyclophilin D, and thus reduces the immunosuppressive effect. That is, cascade targeted therapy to reduce TBI brain damage and save its neurological function.
[0018] This application confirms the application effect of cascade targeted delivery of CsA nanotherapy in protecting against posterior brain injury in TBI mice through research, and on this basis conducts product development and clinical transformation of the drug, which will provide a new and important medical means for clinical TBI treatment and has great research significance and application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 RMP-Lip provided in Example 1 CsA and Lip CsA Transmission electron microscopy characterization diagram;
[0020] Figure 2 RMP-Lip provided in Example 1 CsA and Lip CsA The relationship between particle size and zeta potential;
[0021] Figure 3 The flow cytometry analysis of apoptosis levels in each experimental group provided in Example 2;
[0022] Figure 4 The graph of cell LDH release level detected by ELISA instrument in each experimental group provided in Example 2;
[0023] Figure 5 RMP-Lip provided in Example 3 CsA Effects of treatment on hippocampal astrocyte injury and inflammation in TBI mice 5 days after treatment;
[0024] Figure 6 RMP-Lip provided in Example 3 CsA Figure 5 shows the effects of microglial injury and inflammation on TBI mice after 5 days of treatment;
[0025] Figure 7 RMP-Lip provided in Example 3 CsA Changes of inflammatory factors in peripheral blood of TBI mice after 5 days of treatment;
[0026] Figure 8 RMP-Lip provided in Example 3 CsA Changes in brain function and injury markers after 5 days of treatment in TBI mice;
[0027] Fig. 9 RMP-Lip provided in Example 4 CsA Diagram of changes in the effects on mouse lymphocytes;
[0028] Fig.10 RMP-Lip provided in Example 4 CsA Graph showing changes in the effects on apoptosis of Jurkat E6-1 cells. DETAILED DESCRIPTION
[0029] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0030] <Technical solution>
[0031] First, the present invention provides a brain-targeted cyclosporine A nanomedicine, comprising
[0032] A fusion membrane is a composite membrane comprising a mitochondrial membrane and a cell membrane or organelle membrane fused with the mitochondrial membrane;
[0033] Intercalating molecules are molecules that are modified on the fusion membrane; intercalating molecules are functional molecules that cross the blood-brain barrier;
[0034] The inner cavity is cyclosporine A liposomes; the inner cavity is surrounded by a fusion membrane.
[0035] In the present invention, the functional molecule is DSPE-PEG 2000 -RVG29.
[0036] In the present invention, the cell membrane or organelle membrane fused with the mitochondrial membrane includes at least one of a platelet membrane, a macrophage membrane, a neutrophil membrane, and an erythrocyte membrane.
[0037] Furthermore, the cell membrane or organelle membrane fused with the mitochondrial membrane is a platelet membrane.
[0038] In the present invention, the source of mitochondrial membrane is mitochondria.
[0039] In the present invention, the particle size of the nano drug is 80 to 250 nm.
[0040] Second, the present invention provides a method for preparing the aforementioned brain-targeted cyclosporine A nanomedicine, comprising the following steps:
[0041] S1 prepares cyclosporine A liposomes;
[0042] S2 extracts cell membranes or organelle membranes that fuse with mitochondrial membranes;
[0043] S3 extracts mitochondrial membranes;
[0044] S4 modifies the fusion membrane;
[0045] S5 Nanodrug Preparation.
[0046] In the present invention:
[0047] (1) In S1, cholesterol and lecithin are dissolved in a solvent, injected into PBS with a syringe, and the solvent is removed to obtain cyclosporine A liposomes;
[0048] (2) In S4, the cell membrane or organelle membrane is fused with the mitochondrial membrane and DSPE-PEG is added 2000 -RVG29 is modified to obtain a modified fusion membrane;
[0049] (3) In S5, the modified fusion membrane is mixed with cyclosporine A liposomes and extruded to obtain nanomedicine.
[0050] Third, the present invention provides an application of the aforementioned brain-targeted cyclosporine A nanomedicine in the preparation of a drug for treating brain injury.
[0051] Brain damage includes brain tissue damage caused by stroke or traumatic brain injury, among which stroke includes ischemic stroke and hemorrhagic stroke.
[0052] In ischemic stroke and some types of stroke, interruption of blood supply leads to lack of oxygen and nutrients in brain tissue. In traumatic brain injury, the injury may also cause local blood flow reduction or interruption, resulting in similar ischemic effects. Whether it is stroke, ischemic stroke or traumatic brain injury, it will cause damage to brain tissue and affect brain function. It will trigger a series of neurological symptoms, such as loss of consciousness, headache, cognitive impairment, movement disorders, language disorders, visual problems, etc. The specific symptoms depend on the location and severity of the injury. It may cause oxidative stress, that is, cell damage caused by excessive free radicals and reactive oxygen species. This stress can further damage brain cells and the blood-brain barrier, leading to inflammation and cell death. These brain injury events can lead to apoptosis (programmed cell death) and necrosis (non-programmed cell death). Hypoxia, energy depletion and accumulation of toxic substances can lead to the death of neurons and glial cells. After brain injury, immune cells (such as microglia and macrophages) are activated and release inflammatory mediators, which can further aggravate brain damage. Whether it is a stroke, ischemic stroke or traumatic brain injury, brain edema (fluid accumulation in brain tissue) is a common result. This edema increases intracranial pressure and further damages brain tissue. After injury, the uncontrolled release of neurotransmitters (such as glutamate) can cause excitotoxicity, which can damage neurons.
[0053] Example 1 -RMP-Lip CsA Preparation
[0054] (1) Cyclosporine A liposomes were prepared by ethanol injection method. Specifically, cholesterol, phosphatidylcholine and cyclosporine A were dissolved in an appropriate amount of anhydrous ethanol, the mass ratio of cholesterol, phosphatidylcholine and cyclosporine A was 2:6:3, and the amount of anhydrous ethanol was sufficient to dissolve the above substances; the solution was slowly dripped into PBS preheated at 42°C using a syringe, and the solution was stirred for 2 h using a stirring bar to evaporate the anhydrous ethanol, and then the residual anhydrous ethanol was removed using a rotary evaporator.
[0055] (2) Platelets were extracted from platelets using a platelet extraction kit, and further frozen and thawed in liquid nitrogen three times, and then centrifuged at 3500g for 10 min. The supernatant was centrifuged at 100000g for 1 h to obtain platelet membranes.
[0056] (3) Mitochondria were extracted using a mitochondrial extraction kit, and protease inhibitors were added to further perform low-temperature probe sonication. The mixture was centrifuged at 10,000 g for 10 min, and the supernatant was collected and then centrifuged at 100,000 g for 1 h to ultra-isolate the mitochondrial membrane.
[0057] (4) Synthesis of DSPE-PEG 2000 -RVG29, platelet membrane and mitochondrial membrane were added at a protein weight ratio of 1:1, and fused by low-temperature water bath ultrasound. 2000 -RVG29 was modified on the fusion membrane by ice-water bath ultrasound at a power of 400 W, and the membrane protein was fused with DSPE-PEG 2000 -RVG29 has a mass ratio of 10:1.
[0058] (5) The fusion membrane of platelet membrane and mitochondrial membrane modified with RVG29 peptide and cyclosporin A liposomes were mixed at a ratio of protein mass to phospholipid mass = 1:4, and after ultrasound, they were repeatedly extruded 10 times by a liposome extruder. The ultrasound parameters were: ultrasound for 3 minutes in an ice bath (40w, on for 2s, off for 3s); extrusion parameters: repeated extrusion through 400nm and 200nm polycarbonate porous membranes in turn.
[0059] The RMP-Lip prepared in Example 1 CsA The TEM morphology was characterized and the particle size and zeta potential were measured by dynamic light scattering. Figure 1-Figure 2 shown.
[0060] Figure 1 The RMP-Lip prepared in Example 1 CsA and Lip CsA Transmission electron microscopy characterization diagram.
[0061] Figure 2 The RMP-Lip prepared in Example 1 CsA and LipCsA The relationship between particle size and Zeta potential.
[0062] Example 2
[0063] (I) Establishment and grouping of in vitro H / R-injured 3D neuron cell-BBB model:
[0064] (1) The in vitro blood-brain barrier model EPA was constructed using human brain microvascular endothelial cell line hCMEC / D3, mouse hippocampal neuronal cell line HT22, and mouse brain microvascular pericytes BMPC.
[0065] (2) Before inoculation of cells, rat tail collagen type I (10 μg / cm 2 ) were coated on the top, bottom and bottom of the polyester membrane of the Transwell chamber at room temperature. 4 -9×10 4 Pieces / cm 2 The cells were seeded on the polyester membrane substrate of the chamber at a density of 100 μg / mL and firmly attached to the membrane in a normoxic cell culture incubator at 5% CO2 and 37°C. 4 Pieces / cm 2 The cells were seeded on the top surface of the polyester membrane of the chamber at a density of 5×10 4 Pieces / cm 2 The number of cells was inoculated in the lower chamber for co-culture. From the second day of co-culture, the BBB model was maintained in EGM-2 culture medium. After 10 days of co-culture, a dense cell monolayer was formed (the transendothelial cell resistance reached 325±9Ωcm -2 ). According to FDA recommendations, TEER ≥ 100Ωcm -2 Used for the study of drug transport across the blood-brain barrier in vitro.
[0066] (3) In subsequent experiments, the Transwell polyester membrane used to construct the BBB was transferred to another Transwell lower chamber seeded with HT22 cells at an appropriate density, thereby constructing a hippocampal neuron cell-BBB model.
[0067] (4) Based on the hippocampal neuron cell-BBB model, a BBB model of H / R injury was constructed: before hypoxia and reoxygenation, the hCMEC / D3 cell monolayer was treated with 100 ng / mL TNF-α for 4 h, and then the hippocampal neuron cell-BBB system was replaced with sugar-free and serum-free DMEM medium and cultured in a hypoxic workstation (oxygen concentration 0.4%) for 10 h. Then, the high-glucose 10% FBSDMEM medium was replaced and placed in a normoxic incubator (oxygen concentration 21%) for a continuous co-culture of 14 h.
[0068] (II) Randomization and intervention of hippocampal neuron cell-BBB system:
[0069] (1) Experimental groups
[0070] The posterior hippocampal neuron cell-BBB system cultured in the hypoxia workstation for 10 h was randomly divided into 4 groups. The grouping is shown in Table 1.
[0071] Table 1
[0072] 1 group Control group (n=6) 2 groups H / R group (n=6) 3 groups H / R+LipCsA group (n=6) 4 groups H / R+RMP-LipCsA group (n=6)
[0073] (2) Intervention measures:
[0074] 1) Control group: The system was cultured in a normoxic incubator using conventional DMEM medium for 24 h.
[0075] 2) H / R group: After the hypoxia process was completed, the upper chamber of the Transwell was replaced with a high-glucose 10% FBSDMEM medium containing an equal amount of solvent, and the lower chamber was replaced with a regular high-glucose 10% FBSDMEM medium for reoxygenation culture.
[0076] 3)H / R+Lip CsA Group: After the hypoxia process, the upper chamber of the Transwell was replaced with an equal amount of Lip dissolved in solvent. CsA (CsA final concentration was 5 μM) high-glucose 10% FBSDMEM medium, and the lower chamber was replaced with regular high-glucose 10% FBSDMEM medium for reoxygenation culture.
[0077] 4)H / R+RMP-Lip CsA Group: After the hypoxia process, the upper chamber of the Transwell was replaced with an equal amount of RMP-Lip dissolved in solvent. CsA (CsA final concentration was 5 μM) high-glucose 10% FBSDMEM medium, and the lower chamber was replaced with regular high-glucose 10% FBSDMEM medium for reoxygenation culture.
[0078] Note: H / R stands for hypoxia / reoxygenation.
[0079] (III) Observation indicators:
[0080] After the reoxygenation culture process, the apoptosis level and LDH release of HT22 cells in the lower chamber were detected. Figure 3-4 shown.
[0081] Figure 3 Figure 3 shows the cell apoptosis levels detected by flow cytometry in each experimental group.
[0082] Figure 4 This is a diagram of the cell LDH release level detected by the microplate reader in each experimental group of this example.
[0083] like Figure 3-4As shown in Figure 2, after H / R treatment, the ROS content in HT22 cells in the Transwell chamber increased significantly; CsA With RMP-Lip CsA The intervention could reduce the LDH release in HT22 cells to varying degrees, and compared with H / R+Lip CsA Compared with the H / R+RMP-Lip group CsA The H / R group can significantly reduce the LDH release level. The detection of cell apoptosis also showed the same trend. The apoptotic cell ratio of HT22 cells in the H / R group increased significantly; compared with H / R+Lip CsA Group, H / R+RMP-Lip CsA The apoptotic cell ratio of HT22 cells was most significantly reduced in the 4 groups (all P<0.05).
[0084] Example 3 : Animal experiments
[0085] (I) Establishment of animal model:
[0086] (1) All animals were fasted but not watered 12 hours before the experiment.
[0087] (2) The experimental animals were anesthetized with isoflurane.
[0088] (3) A 10-mm midline incision was made on the skull, and then a 4-mm craniotomy was made in the center of the right parietal bone of the mouse. A precision cortical impactor (YHCI99, Wuhan) was used for controlled cortical impact with a tip diameter of 3.5 mm, an impact velocity of 3 m / s, a deformation depth of 1 mm, and a dune time of 100 ms to induce mild to moderate injury.
[0089] (II) Animal randomization and intervention:
[0090] (1) Experimental groups
[0091] Eight-week-old male C57 mice weighing 25 g were randomly divided into four groups after TBI: Sham group (n=6), TBI group (n=6), TBI+Lip group (n=6), CsA Group (n=6), TBI+RMP-Lip CsA Group (n=6).
[0092] (2) Intervention measures
[0093] 1) Sham group: TBI model was not established, except for the other steps of craniotomy, the sham group was given the same amount of solvent intravenously as the other groups;
[0094] 2) TBI group: TBI model was established, and immediately after TBI, the same amount of solvent was intravenously administered as in other groups;
[0095] 3) TBI+Lip CsA Group: TBI model was established. Immediately after TBI, an equal amount of Lip dissolved in solvent was administered intravenously. CsA (The final concentration of CsA was 10 mg / kg).
[0096] 4) TBI+RMP-Lip CsA Group: TBI model was established, and immediately after TBI, an equal amount of RMP-Lip dissolved in solvent was administered intravenously CsA (The final concentration of CsA was 10 mg / kg).
[0097] Note: Sham-sham operation; TBI-traumatic brain injury; CsA-cyclosporine A.
[0098] (IV) Observation indicators
[0099] (1) RMP-Lip CsA Reduced astrocyte and microglia damage and inflammatory response in mice after TBI. Figure 5-6 shown.
[0100] Figure 5 For RMP-Lip CsA Figure 3 Effects of treatment on hippocampal astrocyte injury and inflammation in mice 5 days after TBI.
[0101] Figure 6 For RMP-Lip CsA Figure 3 Effects of treatment on microglial injury and inflammation in mice 5 days after TBI.
[0102] Depend on Figure 5 and Figure 6 It can be seen that compared with the Sham group, the damage and activation of astrocytes and microglia in the TBI group were significantly increased, while in the TBI+Lip CsA The damage and activation of astrocytes and microglia in the group were only slightly reduced;
[0103] Compared with TBI+Lip CsA Group, TBI+RMP-Lip CsA The damage and activation of astrocytes and microglia in the group were significantly reduced.
[0104] (2) RMP-Lip CsA Reduced inflammatory response in mice after TBI, the results Figure 7 shown.
[0105] Figure 7 A, B, and C are the effect diagrams of ELISA detection of peripheral blood inflammatory cytokines TNF-α (A), IL-1β (B), and IL-6 (C).
[0106] The inflammation levels in peripheral blood also showed the same trend, with the levels of proinflammatory cytokines significantly increased in the TBI group compared with the Sham group;
[0107] Compared with TBI+Lip CsA Group, TBI+RMP-Lip CsA The group could most significantly reduce the levels of proinflammatory cytokines TNF-α, IL-1β and IL-6; the differences among the groups were statistically significant (all P<0.05).
[0108] (3) RMP-Lip CsA The results showed that the improvement of neurological function in TBI mice Figure 8 shown.
[0109] Figure 8 The graphs show the changes in brain function and injury markers in each group of animals after 5 days of treatment. Figure 8 A in the middle is the NDS score; Figure 8 B and C are graphs showing serum NSE and S100β levels detected by ELISA.
[0110] Note: NSE-neuron-specific enolase; S100β-S100β protein; NDS-neurological deficit score; *P<0.05.
[0111] Depend on Figure 8 The NDS score results showed that the TBI group had severe neurological deficits. Among all treatment groups, the most significant improvement in neurological function was in the RMP-Lip group. CsA The levels of serum NSE and S100β also showed the same trend. The levels of serum NSE and S100β in the TBI group were significantly higher than those in the Sham group, while those in the RMP-Lip group were significantly lower than those in the CsA The intervention could significantly reduce the levels of serum NSE and S100β; the differences among the groups were statistically significant (P<0.05).
[0112] Embodiment 4: Improve immunosuppression
[0113] (1) Experimental groups
[0114] Eight-week-old male C57 mice weighing 25 g were randomly divided into three groups after TBI: TBI group (n=6), TBI+CsA group (n=6), TBI+RMP-Lip group (n=6), CsA Group (n=6).
[0115] (2) Intervention measures
[0116] Animal experiments
[0117] 1) TBI group: TBI model was established, and immediately after TBI, the same amount of solvent was intravenously administered as in other groups.
[0118] 2) TBI+CsA group: TBI model was established. After TBI, an equal amount of CsA dissolved in a solvent was administered intravenously (final concentration of CsA was 10 mg / kg) once a day for 5 consecutive days.
[0119] 3) TBI+RMP-Lip CsA Group: TBI model was established. After TBI, an equal amount of RMP-Lip dissolved in solvent was administered intravenously. CsA (CsA final concentration was 10 mg / kg), administered once a day for 5 consecutive days.
[0120] (3) Cell experiments
[0121] 1) Control group: The system was cultured in a normoxic incubator using conventional culture medium for 24 h.
[0122] 2) Lip CsA Group: The system was incubated in a normoxic incubator using a CsA culture medium for 24 h (final CsA concentration was 5 μM).
[0123] 3) RMP-Lip CsA Group: The system was incubated in a normoxic incubator using RMP-Lip CsA culture medium for 24 h (final CsA concentration was 5 μM).
[0124] 3. Observation indicators
[0125] (1) RMP-Lip CsA Improve the immunosuppressive effect of CsA on healthy mice, the results are shown in 9.
[0126] Fig. 9 For RMP-Lip CsA The graph shows the changes in the effects on lymphocytes in healthy mice. Five days after administration, blood was collected to detect the number of lymphocytes in the blood.
[0127] (2) RMP-Lip CsA Reduce CsA-induced apoptosis in Jurkat E6-1 cells. Fig.10 shown.
[0128] Fig.10 For RMP-Lip CsA The changes in the effect on apoptosis of Jurkat E6-1 cells. CsA and RMP-Lip CsAThe cells were co-incubated with Jurkat E6-1 cells at a final concentration of 5 μM CsA, and cell apoptosis was detected by flow cytometry 24 h later.
Claims
1. A brain-targeted cyclosporine A nanodrug, characterized in that: include A fusion membrane is a composite membrane comprising a mitochondrial membrane and a cell membrane or organelle membrane fused with the mitochondrial membrane; intercalating molecules, which are modified on the fusion membrane; Intercalating molecules are functional molecules that cross the blood-brain barrier; The inner cavity is cyclosporine A liposomes; The lumen is surrounded by a fused membrane.
2. The brain-targeted cyclosporine A nanodrug according to claim 1, characterized in that: Functional molecule is DSPE-PEG 2000 -RVG29.
3. The brain-targeted cyclosporine A nanodrug according to claim 1, characterized in that: The cell membrane or organelle membrane fused with the mitochondrial membrane includes at least one of a platelet membrane, a macrophage membrane, a neutrophil membrane, and a red blood cell membrane.
4. The brain-targeted cyclosporine A nanomedicine according to claim 3, characterized in that: The cell membrane or organelle membrane that fuses with the mitochondrial membrane is the platelet membrane.
5. The brain-targeted cyclosporine A nanodrug according to claim 1, characterized in that: The source of mitochondrial membrane is mitochondria.
6. The brain-targeted cyclosporine A nanomedicine according to claim 1, characterized in that: The particle size of nanomedicine is 80 to 250 nm.
7. The method for preparing the brain-targeted cyclosporine A nanomedicine according to any one of claims 1 to 6, characterized in that: The steps include: S1 prepares cyclosporine A liposomes; S2 extracts cell membranes or organelle membranes that fuse with mitochondrial membranes; S3 extracts mitochondrial membranes; S4 modifies the fusion membrane; S5 Nanodrug Preparation.
8. The method for preparing the brain-targeted cyclosporine A nanomedicine according to claim 7, characterized in that: The steps include: The invention comprises at least one of the features (1) to (3): (1) In S1, cholesterol and lecithin are dissolved in a solvent, injected into PBS with a syringe, and the solvent is removed to obtain cyclosporine A liposomes; (2) In S4, the cell membrane or organelle membrane is fused with the mitochondrial membrane and DSPE-PEG is added 2000 -RVG29 is modified to obtain a modified fusion membrane; (3) In S5, the modified fusion membrane is mixed with cyclosporine A liposomes and extruded to obtain nanomedicine.
9. Use of the brain-targeted cyclosporine A nanodrug according to any one of claims 1 to 6, or the brain-targeted cyclosporine A nanodrug according to any one of claims 7 to 8 in the preparation of a drug for treating brain injury.
10. The use according to claim 9, characterized in that: Brain injury includes brain tissue damage caused by stroke or traumatic brain injury; stroke includes ischemic stroke and hemorrhagic stroke.
Citation Information
Cited By
Application of targeted liposome as active ingredient in preparation of medicine for treating ischemic brain injury
CN120570842A
